Peter D Friedmann

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8897323/publications.pdf

Version: 2024-02-01

63 papers 2,695 citations

172457 29 h-index 182427 51 g-index

66 all docs

66
docs citations

66 times ranked 2270 citing authors

#	Article	IF	CITATIONS
1	Recidivism and mortality after in-jail buprenorphine treatment for opioid use disorder. Drug and Alcohol Dependence, 2022, 231, 109254.	3.2	40
2	Uncommon and preventable: Perceptions of diversion of medication for opioid use disorder in jail. Journal of Substance Abuse Treatment, 2022, 138, 108746.	2.8	10
3	Legislatively mandated implementation of medications for opioid use disorders in jails: A qualitative study of clinical, correctional, and jail administrator perspectives. Drug and Alcohol Dependence, 2022, 234, 109394.	3.2	12
4	New standards for a new era: Making JSAT better, not perfect. Journal of Substance Abuse Treatment, 2021, 125, 108366.	2.8	0
5	Massachusetts Justice Community Opioid Innovation Network (MassJCOIN). Journal of Substance Abuse Treatment, 2021, 128, 108275.	2.8	20
6	Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USA. Neurotherapeutics, 2020, 17, 55-69.	4.4	57
7	Correlates of Patient-Centered Care Practices at U.S. Substance Use Disorder Clinics. Psychiatric Services, 2020, 71, 35-42.	2.0	19
8	Editorial: Health equity in substance use disorder treatment. Journal of Substance Abuse Treatment, 2020, 118, 108101.	2.8	0
9	Opioid initiation and injection transition in rural northern New England: A mixed-methods approach. Drug and Alcohol Dependence, 2020, 217, 108256.	3.2	14
10	Editorial: COVID-19 and its impact on SUD treatment. Journal of Substance Abuse Treatment, 2020, 117, 108091.	2.8	1
11	Impact of extended release naltrexone on health-related quality of life in individuals with legal involvement and opioid use disorders. Substance Abuse, 2020, 42, 1-7.	2.3	1
12	Partnering with parents to improve outcomes for substance exposed newborns—a pilot program. Journal of Perinatology, 2020, 40, 1041-1049.	2.0	9
13	The relationship of Medicaid expansion to psychiatric comorbidity care within substance use disorder treatment programs. Journal of Substance Abuse Treatment, 2019, 105, 44-50.	2.8	7
14	Impact of Medicaid Restrictions on Availability of Buprenorphine in Addiction Treatment Programs. American Journal of Public Health, 2019, 109, 434-436.	2.7	34
15	Medicaid coverage in substance use disorder treatment after the affordable care act. Journal of Substance Abuse Treatment, 2019, 102, 1-7.	2.8	35
16	Changes in State Technical Assistance Priorities and Block Grant Funds for Addiction After ACA Implementation. American Journal of Public Health, 2019, 109, 885-891.	2.7	4
17	Incidence of future arrests in adults involved in the criminal justice system with opioid use disorder receiving extended release naltrexone compared to treatment as usual. Drug and Alcohol Dependence, 2019, 194, 482-486.	3.2	9
18	Personal Control Over Decisions to Participate in Research by Persons With Histories of Both Substance Use Disorders and Criminal Justice Supervision. Journal of Empirical Research on Human Research Ethics, 2018, 13, 160-172.	1.3	2

#	Article	IF	Citations
19	Do benefits restrictions limit Medicaid acceptance in addiction treatment? Results from a national study. Journal of Substance Abuse Treatment, 2018, 87, 50-55.	2.8	17
20	Effectiveness, Implementation and Real-World Experience with Extended-Release Naltrexone (XR-NTX): A Special Issue of JSAT. Journal of Substance Abuse Treatment, 2018, 85, 31-33.	2.8	1
21	State-Targeted Funding and Technical Assistance to Increase Access to Medication Treatment for Opioid Use Disorder. Psychiatric Services, 2018, 69, 448-455.	2.0	9
22	Benefit requirements for substance use disorder treatment in state health insurance exchanges. American Journal of Drug and Alcohol Abuse, 2018, 44, 426-430.	2.1	8
23	Relapse to opioid use disorder after inpatient treatment: Protective effect of injection naltrexone. Journal of Substance Abuse Treatment, 2018, 85, 49-55.	2.8	86
24	Do patient characteristics moderate the effect of extended-release naltrexone (XR-NTX) for opioid use disorder?. Journal of Substance Abuse Treatment, 2018, 85, 61-65.	2.8	19
25	Initiation of extended release naltrexone (XR-NTX) for opioid use disorder prior to release from prison. Journal of Substance Abuse Treatment, 2018, 85, 45-48.	2.8	36
26	Healthcare utilization in adults with opioid dependence receiving extended release naltrexone compared to treatment as usual. Journal of Substance Abuse Treatment, 2018, 85, 66-69.	2.8	9
27	Medicaid Benefits For Addiction Treatment Expanded After Implementation Of The Affordable Care Act. Health Affairs, 2018, 37, 1216-1222.	5.2	42
28	Developing an opioid use disorder treatment cascade: A review of quality measures. Journal of Substance Abuse Treatment, 2018, 91, 57-68.	2.8	114
29	How ACA Repeal Would Worsen the Opioid Epidemic. New England Journal of Medicine, 2017, 376, e16.	27.0	24
30	Cost-effectiveness of extended release naltrexone to prevent relapse among criminal justice-involved individuals with a history of opioid use disorder. Addiction, 2017, 112, 1440-1450.	3. 3	34
31	Assessing informed consent in an opioid relapse prevention study with adults under current or recent criminal justice supervision. Journal of Substance Abuse Treatment, 2017, 81, 66-72.	2.8	4
32	Linkages Between Patient-centered Medical Homes and Addiction Treatment Organizations. Medical Care, 2017, 55, 379-383.	2.4	5
33	Commitment and Capacity for Providing Evidence-Based Tobacco Treatment in Us Drug Treatment Facilities. Substance Abuse, 2017, 38, 35-39.	2.3	5
34	The Affordable Care Act Transformation of Substance Use Disorder Treatment. American Journal of Public Health, 2017, 107, 31-32.	2.7	61
35	Mobile technology intervention to improve care coordination between HIV and substance use treatment providers: development, training, and evaluation protocol. Addiction Science & Emp; Clinical Practice, 2017, 12, 8.	2.6	11
36	More beds are not the answer: transforming detoxification units into medication induction centers to address the opioid epidemic. Addiction Science & Practice, 2017, 12, 29.	2.6	16

#	Article	IF	CITATIONS
37	Survey Highlights Differences In Medicaid Coverage For Substance Use Treatment And Opioid Use Disorder Medications. Health Affairs, 2016, 35, 2289-2296.	5.2	89
38	Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders. New England Journal of Medicine, 2016, 374, 1232-1242.	27.0	255
39	Despite Resources From The ACA, Most States Do Little To Help Addiction Treatment Programs Implement Health Care Reform. Health Affairs, 2015, 34, 828-835.	5. 2	86
40	Integration of Substance Abuse Treatment Organizations into Accountable Care Organizations: Results from a National Survey. Journal of Health Politics, Policy and Law, 2015, 40, 797-819.	1.9	56
41	Discrepancies in addressing overdose prevention through prescription monitoring programs. Drug and Alcohol Dependence, 2015, 153, 355-358.	3.2	13
42	Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: Rationale and design of a randomized controlled effectiveness trial. Contemporary Clinical Trials, 2015, 41, 110-117.	1.8	26
43	Effect of an Organizational Linkage Intervention on Staff Perceptions of Medication-Assisted Treatment and Referral Intentions in Community Corrections. Journal of Substance Abuse Treatment, 2015, 50, 50-58.	2.8	67
44	Adoption of Evidence-Based Clinical Innovations. Medical Care Research and Review, 2014, 71, 43-60.	2.1	38
45	Medications for addiction treatment: an opportunity for prescribing clinicians to facilitate remission from alcohol and opioid use disorders. Rhode Island Medical Journal (2013), 2014, 97, 20-4.	0.2	4
46	Initiation of buprenorphine during incarceration and retention in treatment upon release. Journal of Substance Abuse Treatment, 2013, 45, 222-226.	2.8	57
47	Alcohol Use in Adults. New England Journal of Medicine, 2013, 368, 365-373.	27.0	119
48	Medication-Assisted Treatment in Criminal Justice Agencies Affiliated with the Criminal Justice-Drug Abuse Treatment Studies (CJ-DATS): Availability, Barriers, and Intentions. Substance Abuse, 2012, 33, 9-18.	2.3	179
49	A Randomized Trial of Methadone Initiation Prior to Release from Incarceration. Substance Abuse, 2012, 33, 19-29.	2.3	73
50	Just call it "treatment― Addiction Science & Clinical Practice, 2012, 7, 10.	2.6	49
51	Top Manager Effects on Buprenorphine Adoption in Outpatient Substance Abuse Treatment Programs. Journal of Behavioral Health Services and Research, 2010, 37, 322-337.	1.4	28
52	Collaborative Behavioral Management for Drug-Involved Parolees: Rationale and Design of the Step'n Out Study. Journal of Offender Rehabilitation, 2008, 47, 290-318.	0.8	33
53	Evidence-based treatment practices for drug-involved adults in the criminal justice system. Journal of Substance Abuse Treatment, 2007, 32, 267-277.	2.8	148
54	Do Mechanisms that Link Addiction Treatment Patients to Primary Care Influence Subsequent Utilization of Emergency and Hospital Care?. Medical Care, 2006, 44, 8-15.	2.4	51

#	Article	IF	Citations
55	Attitudes and Practices Regarding the Use of Methadone in US State and Federal Prisons. Journal of Urban Health, 2005, 82, 411-419.	3.6	107
56	Designated case managers as facilitators of medical and psychosocial service delivery in addiction treatment programs. Journal of Behavioral Health Services and Research, 2004, 31, 86-97.	1.4	10
57	Predictors of Emergency Medical Services Utilization by Elders. Academic Emergency Medicine, 2003, 10, 52-58.	1.8	29
58	Accessibility of Addiction Treatment: Results from a National Survey of Outpatient Substance Abuse Treatment Organizations. Health Services Research, 2003, 38, 887-903.	2.0	70
59	Predictors of follow-up health status in the Drug Abuse Treatment Outcome Study (DATOS). Drug and Alcohol Dependence, 2003, 69, 243-251.	3.2	28
60	Trends in comprehensive service availability in outpatient drug abuse treatment. Journal of Substance Abuse Treatment, 2003, 24, 81-88.	2.8	51
61	Professional satisfaction experienced when caring for substance-abusing patients. Journal of General Internal Medicine, 2002, 17, 373-376.	2.6	3
62	Screening and intervention for alcohol problems. Journal of General Internal Medicine, 2000, 15, 84-91.	2.6	215
63	The Effect of Alcohol Abuse on the Health Status of Older Adults Seen in the Emergency Department. American Journal of Drug and Alcohol Abuse, 1999, 25, 529-542.	2.1	36